The purpose of the present study was to compare two groups of patients, the first receiving a single dose of rifampicin, in whom eventual competition was looked for, the other receiving the drug for 17 days, the main liver tests being kept under regular observation.
Methods

INGESTION OF A SINGLE DOSE OF RIFAMPICIN
Twelve male patients were studied, 42 to 72 years old. Six of them had alcoholic cirrhosis proved histologically; among these six, two had ascites. The six other patients had livers that were estimated to be normal according to clinical and biological criteria. The BSP fractional clearance was measured from four samples taken during 20 minutes following the injection of BSP (normal: 0.145 ± 1 SD 0.015). In the 'blank' sample obtained before injection, serum concentrations of conjugated bilirubin and unconjugated bilirubin were estimated by the method of Weber and Schalm (1962) (normal: conjugated < 04 mg/100 ml; unconjugated < 0-8 mg/100 ml; total bilirubin < 1.2 mg/100 ml). A single dose of 600 mg of rifampicin was then given orally, the patient being fasting. Fractional clearance of BSP was estimated one hour, three hours, and occa-sionally 24 hours after ingestion. Serum bilirubin concentration was measured after three hours. Determination of the serum concentrations of rifampicin was made one and three hours after the ingestion by an ordinary microbiological assay, based on the diffusion of the antibiotic in agar in the presence of a culture of Bacillus brevis at pH 7.38. Standard curves were obtained by dissolving increasing amounts of rifampicin in normal serum. Each measurement was made in three different dishes, each containing three discs soaked in the unknown sample after appropriate dilution with 0.15 M phosphate buffer pH 7.38, and three discs soaked in a standard solution. Once these examinations had been performed, a treatment of 600 mg of rifampicin per day was started, the antibiotic being taken in a single dose, after an overnight fast. No other drug was given to any of the eight patients during the 17 days of rifampicin administration. The patients remained under daily clinical observation; liver function tests were performed and rifampicin concentrations in the serum determined after the first week of treatment and at the end. In addition, on the 17th day of treatment a liver biopsy was taken in two patients with normal livers.
Results
Except when otherwise stated, all the results are expressed as mean + 1 SD. For comparison of the results, paired analysis, the Student t test, or the Mann-Whitney U test were used (Siegel, 1956 livers. Probably due to the large dispersion of the results, the difference between these two figures is not significant (0.05 < p < 0 10). After three hours the results were respectively 17.08 ± 5.60 for the cirrhotic patients and 10.38 ± 3.68 for the patients with normal livers (p < 0.05).
Fractional clearance of BSP In all patients, at the first hour following ingestion, there was a considerable decrease of the fractional clearance of BSP as compared with the initial figures. This was more pronounced in patients with normal livers (Fig. 1) , although significant at the 5 % level in the cirrhotic patients (Fig. 2) . Three hours after ingestion, BSP clearance was still abnormal and a tendency to return to the initial figures was only observed 24 hours after ingestion of the antibiotic.
Bilirubinaemia
The individual results of bilirubinaemia three hours after ingestion are shown in Figs 3 and 4 in comparison with the initial values. Among the six subjects with normal livers (Fig. 3) , five showed an important increase in unconjugated bilirubin, and hence of total bilirubin. The latter increased from 087 ± 043 mg/100 ml before intake of the drug to 1. three hours afterwards. However, one of the subjects varied in an opposite direction to the others, and the difference was not significant within the limit of 5 %. In the six cirrhotic patients (Fig. 4) , there was a clearer increase in the bilirubin: total bilirubin increased on an average by 75% within the three hours following ingestion of rifampicin (p < 0O001). It should be noted that this increase was essentially due to an increase in the unconjugated fraction but the conjugated bilirubin was also affected.
DURING AND FOLLOWING TREATMENT FOR 17 DAYS Clinical observations
No clinical modification was noted either in patients with normal livers or in those with cirrhosis; in none of these subjects was there any sign of intolerance.
Rifampicin concentrations in serum They were higher in cirrhotic patients than in those with normal livers. The mean of all determinations performed 24 hours after each intake of rifampicin was 1.71 ± 2.30 ,g/ml in the cirrhotic patients, as against 0.038 ± 0073 in the group with normal livers (U = 9, p < O002). The large SD observed in the cirrhotic patients could reflect the variable degree of hepatic involvement.
In the patients with normal livers, the serum concentrations of rifampicin determined at the same time following ingestion of the drug gradually decreased during treatment. On the contrary, in the cirrhotic patients the serum concentrations of rifampicin remained stable throughout the 17 days of treatment (Table I) .
Fractional clearance of BSP (Table II) In the four subjects with normal livers, in comparison with the initial figures, fractional clearance of BSP was always found to be low, and remained so throughout treatment. In the four patients with cirrhosis, the initial values were of course low; they remained so.
Other data No significant modification was ascertained in either of the two groups of patients with regard to bilirubinaemia, SGPT, serum alkaline phosphatases, electrophoresis, or blood clotting factors. In all the patients, creatinaemia and creatinuria were within normal limits. In the two non-cirrhotic patients in whom a liver biopsy was taken on the 17th day of treatment, no abnormalities were observed under light and electron microscopy. (Shotton, Carpenter, and Rinehart, 1961; Nosslin, 1963; Berthelot and Billing, 1966; Erlinger, Emond, Berthelot, Benhamou, and Fauvert, 1966; Berthelot, 1967) . The first slope of BSP disappearance was mainly affected, together with an increase in unconjugated bilirubin; this last seems not to be related to any inhibition of bilirubin UDP-glucuronyl transferase activity of the liver in vitro (P. Berthelot, work in progress) . One would therefore suggest that competition affects the first stage of transfer of organic anions in the liver cell, ie, uptake. Such a competition for uptake could take place on the membrane of the hepatocyte, in which case one must simply admit the existence of identical, however hypothetical, membrane carriers for rifampicin, BSP, and bilirubin. An alternative explanation is that competition for uptake would be located on cytoplasmic acceptor proteins, able to concentrate the organic anions in the hepatic cell (Levi, Gatmaitan, and Arias, 1969) ; for bunamiodyl and male fern extracts at least, there is substantial evidence in favour of this hypothesis (Levi et al, 1969) . The increase in serum bilirubin observed after a single dose of rifampicin affects not only unconjugated but also conjugated bilirubin especially in cirrhotic patients. This suggests that, besides the uptake defect caused by rifampicin, the last stage of hepatic disposal is impaired, ie, the biliary excretion. Such an excretion defect also exists, although only to a slight extent, for at least three drugs acting competitively on the hepatocyte: bunamiodyl (Bolt, Dillon, and Pollard, 1961; Berthelot and Billing, 1966) , male fern extracts (Nosslin and Morgan, 1965) , and novobiocin (Erlinger et al, 1966) . As far as rifampicin is concerned, the defect in excretion is in agreement with the hypocholeretic effect which has been observed in the rat, using high doses of the antibiotic (Keberle, Schmid, and MeyerBrunot, 1969) .
Discussion
Competitions of the type induced by rifampicin can reasonably be considered to be functional abnormalities, directly related to the dose and always reversible when the treatment is discontinued. In no case, has there been any indication that such phenomena would be found together with any structural or ultrastructural modification. At present, it only appears to have one practical outcome: it is illusory to perform a BSP test in patients receiving this type of drug; the BSP test in a patient treated with rifampicin can only be interpreted at least 24 hours after rifampicin administration has been stopped.
In eight patients who received 600 mg/day of rifampicin during 17 days, no changes in liver function tests were observed, except the decreased BSP clearance. These negative results indicate that at doses of rifampicin which were given, and, apart from the competition phenomena already mentioned, there were no other direct (so-called toxic) effects on the liver in any of the patients treated. But it cannot be excluded that rifampicin may, in a small percentage of the patients treated, cause 'idiosyncratic' hepatic disorder; some positive challenges (Lees, Asgher, Hashem, and Sinha, 1970 ) support such hypotheses, as well as the frequency of isolated hypertransaminasaemia (Morere et al, 1969) . In fact, most of the types of jaundice which have been reported appear to be mainly due to conjugated hyperbilirubinaemia. The frequency, however, of these types of jaundice is not higher than that of many other drugs (Zimmerman, 1969) ; such a probability can be considered to be acceptable (1) if the jaundices do not consist in pure cytolytic forms; (2) if the therapeutic efficiency of the drug is unquestionable; (3) if the drug cannot be replaced by another that involves less risk with similar therapeutic efficiency. Rifampicin seems in agreement with these criteria.
In the patients reported here, there were higher serum concentrations of rifampicin in cirrhotic patients than in patients with normal livers. This could be explained (1) by a greater digestive absorption in the cirrhotic patients; but at the present time, there is no argument to support this hypothesis; (2) by a decrease, in cirrhotic patients, of the elimination of the antibiotic by the liver. As the disposal of rifampicin seems to a certain extent similar to that of bilirubin or BSP, a poor elimination of rifampicin by the cirrhotic liver would not be surprising. In fact, the half-life of the antibiotic in the serum is longer in cirrhotic patients (Constans, Saint-Paul, Morin, Bonnaud, and Bariety, 1969) than in subjects with normal livers (Constans et al, 1969; Verbist, 1969) .
Furthermore, rifampicin is metabolized in the liver by desacetylation (Furesz, 1969) ; a decrease of this process is conceivable in cirrhotic patients.
There was a progressive decrease in the serum concentrations of rifampicin in the patients with normal livers. This suggests a gradual induction, ie, stimulation of rifampicin metabolism by the drug itself. The results observed in the bile of patients submitted to surgical drainage of the bile ducts by T-tube seem to confirm this hypothesis: after a week's treatment with rifampicin the output of this antibiotic in the bile was higher on the eighth day than at the beginning of treatment, whereas the serum concentrations of rifampicin were lower (G. Acocella, personal communication) . Moreover, such an induction would also be in accordance with the increase in paranitrophenol glucuronyl transferase activity found in patients treated with rifampi-cin (Hakim, Feldmann, Boucherot, Boivin, Guibout, and Kreis, 1971) . The fact, however, that the cirrhotic patients do not seem to behave in a similar way remains unclear.
Theoretically, it is conceivable that jaundice induced by drugs and classified as 'idiosyncratic' is more frequent in patients in whom there is inefficient catabolism of the drug and who consequently have higher serum concentrations for the same dose administered. Hence it appears logical to advise prescription of smaller doses to patients showing preexisting modifications of their liver function tests. In addition, it would be of value to measure regularly the serum concentrations of rifampicin in patients suffering from any hepatic insufficiency, since effective concentrations can probably be achieved with fairly small doses. 
